- Location
Clinical stage
"-
Vivaldi Biosciences Announced That It Has Signed a Cooperative Agreement with NIAID
Jan 21, 2014Vivaldi Biosciences Inc., a clinical-stage biotechnology company developing live attenuated influenza vaccines (LAIVs) against seasonal and pandemic influenza, today announced that it has signed a Cooperative Research and Development ...
-
Soligenix Announced Significant Steps Forward in The Development of ThermoVax
Jan 17, 2014Soligenix, a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics, ...
Tags: Soligenix, NIAID, ThermoVax, Drs.John Carpenter
-
Trevena Announced Today Initiation of Dosing in BLAST-AHF
Jan 10, 2014Trevena, Inc., a clinical stage pharmaceutical company involved in the discovery and development of G-protein coupled receptor (GPCR) biased ligands, announced today initiation of dosing in BLAST-AHF, the Company's randomized, multi-center ...
Tags: Trevena, GPCR biased ligands, BLAST-AHF, acute heart failure
-
Ocera Therapeutics Has Entered Into a Technology Transfer and License Pact with Roche
Dec 19, 2013Ocera Therapeutics (Nasdaq:OCRX) today announced that it has entered into a Technology Transfer and License Agreement with the Roche Group, including the Research and Early Development arms of both Genentech and Roche, for rights to its ...
Tags: Ocera Therapeutics, Roche, Macrocyclic Template Chemistry
-
BIND Therapeutics Amended Its Development and Commercialization Collaboration Agreement
Dec 16, 2013BIND Therapeutics, a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called Accurins, has amended its development and commercialization collaboration agreement with Amgen to extend the period ...
-
Sorrento Therapeutics Announced a Definitive Agreement to Acquire Concortis Biosystems
Nov 18, 2013Sorrento Therapeutics, a clinical-stage biopharmaceutical company, has announced a definitive agreement to acquire US-based Concortis Biosystems. This acquisition provides Sorrento Therapeutics with a comprehensive technology platform for ...
-
Calithera Biosciences Has Completed a $35m Series D Financing Led by Adage Capital Partner
Nov 1, 2013Calithera Biosciences has completed a $35m series D financing led by Adage Capital Partners, LP. Joining Adage as new investors in this financing are the Longwood Fund and two other institutional investor groups. The transaction also ...
-
Stemline Therapeutics Announce Their Collaboration to Accelerate The Development of SL-401
Oct 31, 2013Stemline Therapeutics, a clinical stage biopharmaceutical company, and The Leukemia & Lymphoma Society (LLS), a voluntary health organization, have announced their collaboration to accelerate the development of SL-401 for the treatment of ...
-
Alzheon Announced The Launch of The Company,The Securing of Initial Private Financing
Oct 28, 2013Alzheon announced the launch of the company, the securing of initial private financing, and the signing of an exclusive license agreement to a novel clinical drug candidate for Alzheimer’s disease, a family of analogs, and a drug ...
Tags: Alzheon, Alzheimer's Disease
-
Sorrento Has Acquired Sherrington Pharmaceuticals for Chronic Pain Treatment
Oct 12, 2013US-based development-stage biopharmaceutical firm Sorrento Therapeutics has acquired Sherrington Pharmaceuticals (Sherrington), a company that provides chronic pain treatment for end-stage cancer patients and other severe pain indications. ...
Tags: Drug, Chronic Pain Treatment
-
Heat Biologics Has Filed an Investigational NDA with FDA for HS-410
Oct 8, 2013US-based clinical stage biopharmaceutical firm Heat Biologics has filed an investigational new drug application (NDA) with the US Food and Drug Administration (FDA) for its second product candidate, HS-410, which will be evaluated in ...
-
CureVac Has Licensing Agreement with Janssen Pharmaceutical to Develop a Messenger RNA
Oct 8, 2013Germany-based clinical stage biopharmaceutical firm CureVac has entered into collaboration and licensing agreement with Janssen Pharmaceuticals to develop a messenger RNA (mRNA)-based influenza vaccine. The deal will see CureVac ...
Tags: Influenza Vaccine, Medicine
-
arGEN-X Has Achieved a Key Success Milestone
Sep 19, 2013arGEN-X, a clinical stage human monoclonal antibody therapeutics company, cin its SIMPLE Antibody research program collaboration with Shire Pharmaceuticals' Human Genetic Therapies division. The milestone, which was the first ...
-
EMA Has Granted an Orphan Drug Status to GlycoMimetics' GMI-1070
Sep 17, 2013The European Medicines Agency (EMA) has granted an orphan drug status to US-based clinical-stage biotechnology company GlycoMimetics' GMI-1070 (rivipansel sodium), designed to treat vaso-occlusive crisis (VOC) in patients with sickle cell ...
-
EMA Has Granted an Orphan Drug Status to US-Based Clinical-Stage Biotechnology Company
Sep 17, 2013The European Medicines Agency (EMA) has granted an orphan drug status to US-based clinical-stage biotechnology company GlycoMimetics’ GMI-1070 (rivipansel sodium), designed to treat vaso-occlusive crisis (VOC) in patients with sickle ...
Tags: Orphan Drug, Cell Drug
